Aspergillus arthritis sits at an unusual crossroads in medicine: it is an infectious disease, an immune disease, and a joint disease all at once. For most people who develop it — typically those on immunosuppressive therapy after an organ transplant, those being treated for blood cancers, or those with rare primary immune deficiencies — the path to diagnosis is rarely smooth.

Joint bleeding while on anticoagulant therapy places you in a narrow corridor: the medication is protecting you from a potentially life-threatening clot, yet the same drug raises your risk of bleeding into the dense, pressure-sensitive tissue of a joint.

If you or someone close to you has been diagnosed with diffuse-type giant cell tumor of the tendon sheath — also known as tenosynovial giant cell tumor, diffuse type, or historically as pigmented villonodular synovitis — you are dealing with one of the rarest soft-tissue conditions in orthopedic oncology.

When arthritis appears after a parechovirus infection, the clinical picture can be surprisingly easy to miss. Human parechovirus (HPeV) is most often associated with neonatal sepsis-like syndromes or childhood meningitis, so when joint inflammation follows — whether in infants recovering from a serious HPeV episode or in adults after a milder infection — it is rarely the first thing on anyone's radar.